Tackling muscle fibrosis: From molecular mechanisms to next generation engineered models to predict drug delivery

S. Bersini, M. Gilardi, M. Mora, S. Krol, C. Arrigoni, C. Candrian, S. Zanotti, M. Moretti

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Muscle fibrosis represents the end stage consequence of different diseases, among which muscular dystrophies, leading to severe impairment of muscle functions. Muscle fibrosis involves the production of several growth factors, cytokines and proteolytic enzymes and is strictly associated to inflammatory processes. Moreover, fibrosis causes profound changes in tissue properties, including increased stiffness and density, lower pH and oxygenation. Up to now, there is no therapeutic approach able to counteract the fibrotic process and treatments directed against muscle pathologies are severely impaired by the harsh conditions of the fibrotic environment. The design of new therapeutics thus need innovative tools mimicking the obstacles posed by the fibrotic environment to their delivery. This review will critically discuss the role of in vivo and 3D in vitro models in this context and the characteristics that an ideal model should possess to help the translation from bench to bedside of new candidate anti-fibrotic agents.

Original languageEnglish
Pages (from-to)64-77
Number of pages14
JournalAdvanced Drug Delivery Reviews
Volume129
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Fibrosis
Muscles
Pharmaceutical Preparations
Muscular Dystrophies
Intercellular Signaling Peptides and Proteins
Peptide Hydrolases
Pathology
Cytokines
Therapeutics

Keywords

  • 3D in vitro models
  • Muscular dystrophy
  • Skeletal muscle fibrosis

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Tackling muscle fibrosis : From molecular mechanisms to next generation engineered models to predict drug delivery. / Bersini, S.; Gilardi, M.; Mora, M.; Krol, S.; Arrigoni, C.; Candrian, C.; Zanotti, S.; Moretti, M.

In: Advanced Drug Delivery Reviews, Vol. 129, 01.04.2018, p. 64-77.

Research output: Contribution to journalReview article

Bersini, S. ; Gilardi, M. ; Mora, M. ; Krol, S. ; Arrigoni, C. ; Candrian, C. ; Zanotti, S. ; Moretti, M. / Tackling muscle fibrosis : From molecular mechanisms to next generation engineered models to predict drug delivery. In: Advanced Drug Delivery Reviews. 2018 ; Vol. 129. pp. 64-77.
@article{5664ec50ca1a4761bdd9583a5c0fc101,
title = "Tackling muscle fibrosis: From molecular mechanisms to next generation engineered models to predict drug delivery",
abstract = "Muscle fibrosis represents the end stage consequence of different diseases, among which muscular dystrophies, leading to severe impairment of muscle functions. Muscle fibrosis involves the production of several growth factors, cytokines and proteolytic enzymes and is strictly associated to inflammatory processes. Moreover, fibrosis causes profound changes in tissue properties, including increased stiffness and density, lower pH and oxygenation. Up to now, there is no therapeutic approach able to counteract the fibrotic process and treatments directed against muscle pathologies are severely impaired by the harsh conditions of the fibrotic environment. The design of new therapeutics thus need innovative tools mimicking the obstacles posed by the fibrotic environment to their delivery. This review will critically discuss the role of in vivo and 3D in vitro models in this context and the characteristics that an ideal model should possess to help the translation from bench to bedside of new candidate anti-fibrotic agents.",
keywords = "3D in vitro models, Muscular dystrophy, Skeletal muscle fibrosis",
author = "S. Bersini and M. Gilardi and M. Mora and S. Krol and C. Arrigoni and C. Candrian and S. Zanotti and M. Moretti",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.addr.2018.02.009",
language = "English",
volume = "129",
pages = "64--77",
journal = "Advanced Drug Delivery Reviews",
issn = "0169-409X",
publisher = "Elsevier",

}

TY - JOUR

T1 - Tackling muscle fibrosis

T2 - From molecular mechanisms to next generation engineered models to predict drug delivery

AU - Bersini, S.

AU - Gilardi, M.

AU - Mora, M.

AU - Krol, S.

AU - Arrigoni, C.

AU - Candrian, C.

AU - Zanotti, S.

AU - Moretti, M.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Muscle fibrosis represents the end stage consequence of different diseases, among which muscular dystrophies, leading to severe impairment of muscle functions. Muscle fibrosis involves the production of several growth factors, cytokines and proteolytic enzymes and is strictly associated to inflammatory processes. Moreover, fibrosis causes profound changes in tissue properties, including increased stiffness and density, lower pH and oxygenation. Up to now, there is no therapeutic approach able to counteract the fibrotic process and treatments directed against muscle pathologies are severely impaired by the harsh conditions of the fibrotic environment. The design of new therapeutics thus need innovative tools mimicking the obstacles posed by the fibrotic environment to their delivery. This review will critically discuss the role of in vivo and 3D in vitro models in this context and the characteristics that an ideal model should possess to help the translation from bench to bedside of new candidate anti-fibrotic agents.

AB - Muscle fibrosis represents the end stage consequence of different diseases, among which muscular dystrophies, leading to severe impairment of muscle functions. Muscle fibrosis involves the production of several growth factors, cytokines and proteolytic enzymes and is strictly associated to inflammatory processes. Moreover, fibrosis causes profound changes in tissue properties, including increased stiffness and density, lower pH and oxygenation. Up to now, there is no therapeutic approach able to counteract the fibrotic process and treatments directed against muscle pathologies are severely impaired by the harsh conditions of the fibrotic environment. The design of new therapeutics thus need innovative tools mimicking the obstacles posed by the fibrotic environment to their delivery. This review will critically discuss the role of in vivo and 3D in vitro models in this context and the characteristics that an ideal model should possess to help the translation from bench to bedside of new candidate anti-fibrotic agents.

KW - 3D in vitro models

KW - Muscular dystrophy

KW - Skeletal muscle fibrosis

UR - http://www.scopus.com/inward/record.url?scp=85043601302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043601302&partnerID=8YFLogxK

U2 - 10.1016/j.addr.2018.02.009

DO - 10.1016/j.addr.2018.02.009

M3 - Review article

AN - SCOPUS:85043601302

VL - 129

SP - 64

EP - 77

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

SN - 0169-409X

ER -